Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$14.5M Buy
63,344
+224
+0.4% +$51K 0.85% 26
2025
Q3
$14.6M Sell
63,120
-150
-0.2% -$30.5K 0.89% 24
2025
Q2
$11.7M Sell
63,270
-39,083
-38% -$7.26M 0.77% 26
2025
Q1
$21.4M Buy
102,353
+1,063
+1% +$207K 1.53% 13
2024
Q4
$18M Buy
101,290
+1,208
+1% +$222K 1.22% 16
2024
Q3
$19.8M Buy
100,082
+688
+0.7% +$128K 1.36% 15
2024
Q2
$17M Sell
99,394
-2,704
-3% -$448K 1.28% 14
2024
Q1
$18.6M Sell
102,098
-875
-0.8% -$151K 1.35% 16
2023
Q4
$16M Sell
102,973
-498
-0.5% -$72.6K 1.3% 15
2023
Q3
$15.4M Sell
103,471
-1,287
-1% -$189K 1.36% 13
2023
Q2
$14.1M Buy
104,758
+5,698
+6% +$836K 1.23% 14
2023
Q1
$15.8M Buy
99,060
+736
+0.7% +$113K 1.45% 14
2022
Q4
$15.9M Buy
98,324
+1,051
+1% +$161K 1.47% 12
2022
Q3
$13.1M Buy
97,273
+16,415
+20% +$2.36M 1.35% 12
2022
Q2
$12.4M Sell
80,858
-1,071
-1% -$164K 1.78% 9
2022
Q1
$13.3M Sell
81,929
-11,256
-12% -$1.64M 1.65% 13
2021
Q4
$12.6M Buy
93,185
+973
+1% +$115K 1.57% 13
2021
Q3
$9.95M Buy
92,212
+313
+0.3% +$35.8K 1.39% 15
2021
Q2
$10.4M Buy
91,899
+1,112
+1% +$125K 1.5% 14
2021
Q1
$9.82M Sell
90,787
-1,070
-1% -$114K 1.49% 14
2020
Q4
$9.84M Buy
91,857
+5,568
+6% +$535K 1.54% 11
2020
Q3
$7.56M Sell
86,289
-1,047
-1% -$98.6K 1.49% 17
2020
Q2
$8.57M Buy
87,336
+2,118
+2% +$186K 1.77% 9
2020
Q1
$6.49M Buy
85,218
+4,212
+5% +$359K 1.64% 10
2019
Q4
$7.17M Buy
81,006
+316
+0.4% +$26.2K 1.33% 12
2019
Q3
$6.11M Buy
80,690
+33,869
+72% +$2.32M 0.58% 25
2019
Q2
$3.4M Buy
46,821
+3,466
+8% +$272K 0.33% 56
2019
Q1
$3.49M Buy
43,355
+770
+2% +$63K 0.35% 50
2018
Q4
$3.93M Buy
42,585
+2,382
+6% +$209K 0.46% 34
2018
Q3
$3.8M Buy
40,203
+366
+0.9% +$34.7K 0.35% 42
2018
Q2
$3.69M Buy
39,837
+13,321
+50% +$1.3M 0.33% 43
2018
Q1
$2.51M Buy
26,516
+362
+1% +$39.8K 0.24% 58
2017
Q4
$2.53M Buy
+26,154
New +$2.46M 0.24% 59

Other funds holding ABBV

Cadence Bank's ABBV Position: Q4 2025 in Review

Cadence Bank increased its AbbVie (ABBV) stake by 0.35% in Q4 2025, buying an estimated $51K and bringing the position to 63,344 shares worth $14.5M. The position accounts for 0.85% of the portfolio, ranked #26.

Cadence Bank first reported a position in ABBV in Q4 2017 and has held it in 33 quarters since. The position peaked at $21.4M in Q1 2025. 4,147 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Cadence Bank held 63,344 shares of AbbVie worth $14.5M as of Q4 2025.
  • Cadence Bank bought 224 AbbVie shares in Q4 2025, an estimated $51K.
  • AbbVie made up 0.85% of Cadence Bank's portfolio in Q4 2025, its #26 holding.
  • Cadence Bank first reported a position in AbbVie in Q4 2017 and has held it in 33 quarters since.
  • Cadence Bank's AbbVie position peaked at $21.4M in Q1 2025.
  • 4,147 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Cadence Bank's 13F filing for Q4 2025, filed 30 Jan 2026.